亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

山東濟南市偉都化工有限公司  

原料藥,醫藥中間體司產品包括抗腫瘤類原料藥,消炎鎮痛類原料藥,減肥類原料藥,吡啶類中間體,吡啶硼酸類中間體,苯硼酸類中間體,嘧啶類中間體,碘吡啶類中間體,咪唑類中間體,吲哚類中間體及其他類中間體等,可定制生產。

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:洪劍
  • 電話:0531-55503856
  • 傳真:0531-88873470
  • QQ:2497947303
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 吡羅昔康 36322-90-4
吡羅昔康 36322-90-4
單價 155.00 / 千克對比
銷量 暫無
發貨 山東濟南市付款后3天內
庫存 1000千克起訂1千克
品牌 偉都化工
型號 36322-90-4
規格 吡羅昔康 36322-90-4
過期 長期有效
更新 2011-09-23 17:07
 
詳細信息


吡羅昔康 36322-90-4

英文名  Piroxicam
別名  4-Hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide
產品名稱  吡羅昔康; 2-甲基-4-羥基-N-(2-吡啶基)-2H-1,2-苯并噻嗪-3-甲酰胺-1,1-二氧化物

分子式  C15H13N3O4S
分子量  331.34
CAS 登錄號  36322-90-4
EINECS 登錄號  252-974-3

©2025 山東濟南市偉都化工有限公司 版權所有   技術支持:化工網   訪問量:6028  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |